Home
Clinical Trials
A022101/ERASur

Total Ablative Therapy for Patients With Limited Metastatic Colorectal Cancer

Short Title: A022101/ERASur

Enrollment Status: Recruiting

NCT #: NCT05673148

Specialty Area: Oncology

Condition Studied: Oligometastatic Colorectal Cancer

Age Groups: Adult; Older Adult

Phase: II

Study Information

Summary / Purpose

To find out if combining chemotherapy with ablative therapy improves outcomes for patients with colorectal cancer that has spread to a limited number of places.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with colorectal cancer that has spread to a limited number of other areas (up to 4)
Must be eligible for ablative therapy to treat metastatic sites
No prior systemic therapy for metastatic disease

What's Involved

Participation in the study will include:

Intravenous (IV) standard chemotherapy using modified FOLFOX
Ablative therapy to treat metastatic tumors (e.g., radiation or other local treatments) for some patients
CT/MRI scans to monitor response to treatment
Blood and urine samples to check your health and how the treatment is working
Questionnaires

Principal Investigator

Harry Menon, DO

Oncology

A Member of

(775) 982–2820

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT05673148

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews